Trials / Completed
CompletedNCT05799456
Glycosaminoglycan Scores as Early Detection Biomarkers in Bladder Urothelial Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 106 (actual)
- Sponsor
- Jens Nielsen · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Early detection of bladder cancer (BCa) is considered an effective strategy to curb mortality from the disease. However, current urinary biomarkers have insufficient specificity to warrant BCa screening. Urine free glycosaminoglycan profiles (or GAGomes) are promising noninvasive biomarkers of cancer metabolism. In this study, samples are obtained from patients with BCa and controls to compare the glycosaminoglycan profiles between groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Free glycosaminoglycan profiling | Free glycosaminoglycan profiling (GAGome) analysis was performed at a single blinded central laboratory using commercial kits wherein the concentration (in µg/mL) of 17 chondroitin sulfate (CS), heparan sulfate (HS), hyaluronic acid (HA) disaccharides were detected and quantified using a UHPLC-MS/MS system. |
Timeline
- Start date
- 2018-10-01
- Primary completion
- 2023-02-28
- Completion
- 2023-02-28
- First posted
- 2023-04-05
- Last updated
- 2023-04-05
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT05799456. Inclusion in this directory is not an endorsement.